Gamma Investing LLC Blueprint Medicines Corp Transaction History

Gamma Investing LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 14, 2025	SELL	$79.22 - $128.4 $6,020 - $9,758	-76 Reduced 23.31%	250 $32 Million
Q1 2025 Apr 14, 2025	SELL	$86.69 - $115.63 $2.47 Million - $3.3 Million	-28,528 Reduced 98.87%	326 $28.9 Million
Q1 2025 Apr 07, 2025	BUY	$86.69 - $115.63 $2.48 Million - $3.31 Million	28,615 Added 11972.8%	28,854 $326,000
Q4 2024 Jan 02, 2025	BUY	$82.48 - $101.39 $4,288 - $5,272	52 Added 27.81%	239 $20.8 Million
Q3 2024 Oct 04, 2024	BUY	$84.1 - $120.5 $84 - $120	1 Added 0.54%	187 $17.3 Million

Q2 2024 Jul 02, 2024	BUY	$85.18 - $108.78 $5,281 - $6,744	62 Added 50.0%	186 $20 Million
Q1 2024 Apr 05, 2024	BUY	$73.17 - $99.79 $1,975 - $2,694	27 Added 27.84%	124 $11.8 Million
Q4 2023 Feb 01, 2024	BUY	$43.96 - $92.84 $4,264 - $9,005	97 New	97 $7.71 Million

8.54M

14.8K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

Stay updated on Gamma Investing LLC with notifications on news.